Your search found the following article in our index:
Onglyza licence extended for use in combination with insulin
MIMS News, 2012
Onglyza (saxagliptin) can now be prescribed in combination with insulin for adults with type 2 diabetes, with or without metformin, when diet and exercise plus insulin alone do not provide adequate glycaemic control.
In a randomised, double-blind, placebo-controlled study (n=455), added to therapy (with or without ) in patients with inadequate glycaemic control significantly reduced HbA 1c and postprandial glucose levels compared with placebo at week 24.
In an extension of the initial study, saxagliptin maintained the reduction in HbA 1c levels at week 52 compared with placebo.
View rest of article at www.mims.co.uk «
Related articles
Below are some of our articles related to the article above:
intentionally blank
